![]() |
|
|
Vol. 280, Issue 3, 1374-1382, 1997
Addiction Research Foundation, 33 Russell Street, Toronto, Ontario,
M5S 2S1 (D.M.T., S.V.O., N.J., N.Y.L., R.F.T., E.M.S.) and Departments
of
Pharmacology, Medicine and Psychiatry, University of Toronto,
Toronto, Ontario, Canada (R.F.T., E.M.S.) and
Center for Drug and
Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia
(R.B.)
Humans that lack cytochrome P450 2D6 (CYP2D6) activity may have an
altered risk of drug dependence or abuse because this enzyme is
important in the metabolism of some drugs of abuse, including hydrocodone. In rats, hydrocodone conversion to hydromorphone is
catalyzed by CYP2D1, the rat homolog of the human CYP2D6. To determine
the impact of impaired hydromorphone formation on the behavioral
effects of the parent compound, hydrocodone-induced analgesia and
hyperactivity, hydrocodone discrimination and self-administration were
examined in male Wistar rats, with or without pretreatment with CYP2D1
inhibitors (quinine and budipine). In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) produced a marked suppression in brain
and plasma hydromorphone levels detected after the peripheral administration of hydrocodone, thus confirming that the doses used
suppressed CYP2D1 activity. In contrast, CYP2D1 inhibition had no
impact on the analgesic or discriminative stimulus effects of
hydrocodone, nor did this type of manipulation alter hydrocodone self-administration. The effects of quinine on the locomotor activating effects of hydrocodone were subtle at best. Because inhibition of
CYP2D1 in this rat strain is proposed to be a useful animal counterpart
for studying the impact of CYP2D6 polymorphism in humans, these data
suggest that differences in CYP2D6 phenotype will have limited
influence on the drug response to hydrocodone after nonoral
administration. This has recently been verified in a study showing that
inhibition of hydrocodone biotransformation to hydromorphone does not
affect measures of abuse liability. Therefore, hydrocodone's
behavioral effects are most likely attributable to its own intrinsic
effects at mu opioid receptors.
This article has been cited by other articles:
![]() |
S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Peckham and J. R. Traynor Comparison of the Antinociceptive Response to Morphine and Morphine-Like Compounds in Male and Female Sprague-Dawley Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1195 - 1201. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lalovic, B. Phillips, L. L. Risler, W. Howald, and D. D. Shen QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES Drug Metab. Dispos., April 1, 2004; 32(4): 447 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Thompson, H. Wojno, E. Greiner, E. L. May, K. C. Rice, and D. E. Selley Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at {micro}- and {delta}-Opioid Receptors J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 547 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Garrido, O. Sayar, C. Segura, J. Rapado, M. C. Dios-Vieitez, M. J. Renedo, and I. F. Troconiz Pharmacokinetic/Pharmacodynamic Modeling of the Antinociceptive Effects of (+)-Tramadol in the Rat: Role of Cytochrome P450 2D Activity J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 710 - 718. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Watanabe, Y. Tarumi, D. Oneschuk, P. Lawlor, R. K. Portenoy, and R. A. Indelicato Opioid Rotation to Methadone: Proceed With Caution J. Clin. Oncol., May 1, 2002; 20(9): 2409 - 2410. [Full Text] [PDF] |
||||
![]() |
D. G. Williams, D. J. Hatch, and R. F. Howard Codeine phosphate in paediatric medicine Br. J. Anaesth., March 1, 2001; 86(3): 413 - 421. [Abstract] [Full Text] [PDF] |
||||